181 related articles for article (PubMed ID: 26947771)
1. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.
de Moraes NV; Lauretti GR; Coelho EB; Godoy AL; Neves DV; Lanchote VL
Fundam Clin Pharmacol; 2016 Apr; 30(2):153-61. PubMed ID: 26947771
[TBL] [Abstract][Full Text] [Related]
2. Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers.
de Moraes NV; Lauretti GR; Lanchote VL
J Pharm Pharmacol; 2014 Sep; 66(9):1222-30. PubMed ID: 24717054
[TBL] [Abstract][Full Text] [Related]
3. Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of
Haage P; Kronstrand R; Josefsson M; Calistri S; van Schaik RHN; Green H; Kugelberg FC
Pharmacol Res Perspect; 2018 Jul; 6(4):e00419. PubMed ID: 29992026
[TBL] [Abstract][Full Text] [Related]
4. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.
Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ
Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
[TBL] [Abstract][Full Text] [Related]
6. Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics.
Saiz-Rodríguez M; Ochoa D; Román M; Zubiaur P; Koller D; Mejía G; Abad-Santos F
Pharmacogenomics; 2020 Jul; 21(10):663-675. PubMed ID: 32538291
[TBL] [Abstract][Full Text] [Related]
7. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
[TBL] [Abstract][Full Text] [Related]
8. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.
Saarikoski T; Saari TI; Hagelberg NM; Backman JT; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
Eur J Clin Pharmacol; 2015 Mar; 71(3):321-7. PubMed ID: 25560051
[TBL] [Abstract][Full Text] [Related]
9. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.
Shiran MR; Lennard MS; Iqbal MZ; Lagundoye O; Seivewright N; Tucker GT; Rostami-Hodjegan A
Br J Clin Pharmacol; 2009 Jan; 67(1):29-37. PubMed ID: 19133059
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.
Coller JK; Michalakas JR; James HM; Farquharson AL; Colvill J; White JM; Somogyi AA
Br J Clin Pharmacol; 2012 Nov; 74(5):835-41. PubMed ID: 22369095
[TBL] [Abstract][Full Text] [Related]
11. Enantioselective analysis of unbound tramadol, O-desmethyltramadol and N-desmethyltramadol in plasma by ultrafiltration and LC-MS/MS: application to clinical pharmacokinetics.
de Moraes NV; Lauretti GR; Napolitano MN; Santos NR; Godoy AL; Lanchote VL
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jan; 880(1):140-7. PubMed ID: 22173007
[TBL] [Abstract][Full Text] [Related]
12. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
Fliegert F; Kurth B; Göhler K
Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
[TBL] [Abstract][Full Text] [Related]
13. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers.
Pedersen RS; Damkier P; Brøsen K
Eur J Clin Pharmacol; 2006 Jul; 62(7):513-21. PubMed ID: 16763825
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
Gan SH; Ismail R; Wan Adnan WA; Zulmi W
Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
[TBL] [Abstract][Full Text] [Related]
15. Another once-daily formulation of tramadol (Ryzolt).
Med Lett Drugs Ther; 2010 May; 52(1338):39-40. PubMed ID: 20467357
[No Abstract] [Full Text] [Related]
16. Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity.
Allegaert K; Anderson BJ; Verbesselt R; Debeer A; de Hoon J; Devlieger H; Van Den Anker JN; Tibboel D
Br J Anaesth; 2005 Aug; 95(2):231-9. PubMed ID: 15951326
[TBL] [Abstract][Full Text] [Related]
17. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
[TBL] [Abstract][Full Text] [Related]
18. Strategies for Determining Correct Cytochrome P450 Contributions in Hepatic Clearance Predictions: In Vitro-In Vivo Extrapolation as Modelling Approach and Tramadol as Proof-of Concept Compound.
T'jollyn H; Snoeys J; Van Bocxlaer J; De Bock L; Annaert P; Van Peer A; Allegaert K; Mannens G; Vermeulen A; Boussery K
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):537-543. PubMed ID: 27317395
[TBL] [Abstract][Full Text] [Related]
19. Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.
T'jollyn H; Snoeys J; Vermeulen A; Michelet R; Cuyckens F; Mannens G; Van Peer A; Annaert P; Allegaert K; Van Bocxlaer J; Boussery K
AAPS J; 2015 Nov; 17(6):1376-87. PubMed ID: 26209290
[TBL] [Abstract][Full Text] [Related]
20. Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6-Mediated Substrate.
Srinivas NR
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):272-5. PubMed ID: 26367475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
